Macrophage CD40-signaling drives experimental autoimmune encephalomyelitis

Suzanne A B M Aarts, Tom T P Seijkens, Pascal J H Kusters, Claudia M van Tiel, Myrthe E Reiche, Myrthe den Toom, Linda Beckers, Cindy P A A van Roomen, Menno P J de Winther, Gijs Kooij, Esther Lutgens

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

The co-stimulatory CD40L-CD40 dyad plays a major role in multiple sclerosis (MS). CD40 is highly expressed on MHCII+ B cells, dendritic cells and macrophages in human MS lesions. Here we investigated the role of the CD40 downstream signaling intermediates TRAF2 and TRAF6 in MHCII+ cells in experimental autoimmune encephalomyelitis (EAE). Both MHCII-CD40-Traf2-/- and MHCII-CD40-Traf6-/- mice showed a reduction in clinical signs of EAE and prevented demyelination. However, only MHCII-CD40-Traf6-/- mice displayed a decrease in myeloid and lymphoid cell infiltration into the central nervous system (CNS) that was accompanied by reduced levels of TNF-α, IL-6, and IFN-γ. As CD40-TRAF6 interactions predominantly occur in macrophages, we subjected CD40flfl LysMcre mice to EAE. This myeloid specific deletion of CD40 resulted in a significant reduction in EAE severity, reduced CNS inflammation and demyelination. In conclusion, the CD40-TRAF6 signaling pathway in MHCII+ cells plays a key role in neuro-inflammation and demyelination during EAE. Concomitant with the fact that CD40-TRAF6 interactions are predominant in macrophages, depletion of myeloid CD40 also reduces neuro-inflammation. CD40-TRAF6 interactions thus represent a promising therapeutic target for multiple sclerosis.

Original languageEnglish
Pages (from-to)471-480
Number of pages10
JournalJournal of Pathology
Volume247
Issue number4
Early online date24 Nov 2018
DOIs
Publication statusPublished - 1 Apr 2019

Cite this

Aarts, S. A. B. M., Seijkens, T. T. P., Kusters, P. J. H., van Tiel, C. M., Reiche, M. E., den Toom, M., ... Lutgens, E. (2019). Macrophage CD40-signaling drives experimental autoimmune encephalomyelitis. Journal of Pathology, 247(4), 471-480. https://doi.org/10.1002/path.5205
Aarts, Suzanne A B M ; Seijkens, Tom T P ; Kusters, Pascal J H ; van Tiel, Claudia M ; Reiche, Myrthe E ; den Toom, Myrthe ; Beckers, Linda ; van Roomen, Cindy P A A ; de Winther, Menno P J ; Kooij, Gijs ; Lutgens, Esther. / Macrophage CD40-signaling drives experimental autoimmune encephalomyelitis. In: Journal of Pathology. 2019 ; Vol. 247, No. 4. pp. 471-480.
@article{d093c80085144cee9690483de41fe1cb,
title = "Macrophage CD40-signaling drives experimental autoimmune encephalomyelitis",
abstract = "The co-stimulatory CD40L-CD40 dyad plays a major role in multiple sclerosis (MS). CD40 is highly expressed on MHCII+ B cells, dendritic cells and macrophages in human MS lesions. Here we investigated the role of the CD40 downstream signaling intermediates TRAF2 and TRAF6 in MHCII+ cells in experimental autoimmune encephalomyelitis (EAE). Both MHCII-CD40-Traf2-/- and MHCII-CD40-Traf6-/- mice showed a reduction in clinical signs of EAE and prevented demyelination. However, only MHCII-CD40-Traf6-/- mice displayed a decrease in myeloid and lymphoid cell infiltration into the central nervous system (CNS) that was accompanied by reduced levels of TNF-α, IL-6, and IFN-γ. As CD40-TRAF6 interactions predominantly occur in macrophages, we subjected CD40flfl LysMcre mice to EAE. This myeloid specific deletion of CD40 resulted in a significant reduction in EAE severity, reduced CNS inflammation and demyelination. In conclusion, the CD40-TRAF6 signaling pathway in MHCII+ cells plays a key role in neuro-inflammation and demyelination during EAE. Concomitant with the fact that CD40-TRAF6 interactions are predominant in macrophages, depletion of myeloid CD40 also reduces neuro-inflammation. CD40-TRAF6 interactions thus represent a promising therapeutic target for multiple sclerosis.",
keywords = "CD40, TNF receptor-associated peptides and proteins, experimental autoimmune encephalomyelitis, macrophages, multiple sclerosis",
author = "Aarts, {Suzanne A B M} and Seijkens, {Tom T P} and Kusters, {Pascal J H} and {van Tiel}, {Claudia M} and Reiche, {Myrthe E} and {den Toom}, Myrthe and Linda Beckers and {van Roomen}, {Cindy P A A} and {de Winther}, {Menno P J} and Gijs Kooij and Esther Lutgens",
note = "This article is protected by copyright. All rights reserved.",
year = "2019",
month = "4",
day = "1",
doi = "10.1002/path.5205",
language = "English",
volume = "247",
pages = "471--480",
journal = "Journal of Pathology",
issn = "0022-3417",
publisher = "John Wiley and Sons Ltd",
number = "4",

}

Aarts, SABM, Seijkens, TTP, Kusters, PJH, van Tiel, CM, Reiche, ME, den Toom, M, Beckers, L, van Roomen, CPAA, de Winther, MPJ, Kooij, G & Lutgens, E 2019, 'Macrophage CD40-signaling drives experimental autoimmune encephalomyelitis' Journal of Pathology, vol. 247, no. 4, pp. 471-480. https://doi.org/10.1002/path.5205

Macrophage CD40-signaling drives experimental autoimmune encephalomyelitis. / Aarts, Suzanne A B M; Seijkens, Tom T P; Kusters, Pascal J H; van Tiel, Claudia M; Reiche, Myrthe E; den Toom, Myrthe; Beckers, Linda; van Roomen, Cindy P A A; de Winther, Menno P J; Kooij, Gijs; Lutgens, Esther.

In: Journal of Pathology, Vol. 247, No. 4, 01.04.2019, p. 471-480.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Macrophage CD40-signaling drives experimental autoimmune encephalomyelitis

AU - Aarts, Suzanne A B M

AU - Seijkens, Tom T P

AU - Kusters, Pascal J H

AU - van Tiel, Claudia M

AU - Reiche, Myrthe E

AU - den Toom, Myrthe

AU - Beckers, Linda

AU - van Roomen, Cindy P A A

AU - de Winther, Menno P J

AU - Kooij, Gijs

AU - Lutgens, Esther

N1 - This article is protected by copyright. All rights reserved.

PY - 2019/4/1

Y1 - 2019/4/1

N2 - The co-stimulatory CD40L-CD40 dyad plays a major role in multiple sclerosis (MS). CD40 is highly expressed on MHCII+ B cells, dendritic cells and macrophages in human MS lesions. Here we investigated the role of the CD40 downstream signaling intermediates TRAF2 and TRAF6 in MHCII+ cells in experimental autoimmune encephalomyelitis (EAE). Both MHCII-CD40-Traf2-/- and MHCII-CD40-Traf6-/- mice showed a reduction in clinical signs of EAE and prevented demyelination. However, only MHCII-CD40-Traf6-/- mice displayed a decrease in myeloid and lymphoid cell infiltration into the central nervous system (CNS) that was accompanied by reduced levels of TNF-α, IL-6, and IFN-γ. As CD40-TRAF6 interactions predominantly occur in macrophages, we subjected CD40flfl LysMcre mice to EAE. This myeloid specific deletion of CD40 resulted in a significant reduction in EAE severity, reduced CNS inflammation and demyelination. In conclusion, the CD40-TRAF6 signaling pathway in MHCII+ cells plays a key role in neuro-inflammation and demyelination during EAE. Concomitant with the fact that CD40-TRAF6 interactions are predominant in macrophages, depletion of myeloid CD40 also reduces neuro-inflammation. CD40-TRAF6 interactions thus represent a promising therapeutic target for multiple sclerosis.

AB - The co-stimulatory CD40L-CD40 dyad plays a major role in multiple sclerosis (MS). CD40 is highly expressed on MHCII+ B cells, dendritic cells and macrophages in human MS lesions. Here we investigated the role of the CD40 downstream signaling intermediates TRAF2 and TRAF6 in MHCII+ cells in experimental autoimmune encephalomyelitis (EAE). Both MHCII-CD40-Traf2-/- and MHCII-CD40-Traf6-/- mice showed a reduction in clinical signs of EAE and prevented demyelination. However, only MHCII-CD40-Traf6-/- mice displayed a decrease in myeloid and lymphoid cell infiltration into the central nervous system (CNS) that was accompanied by reduced levels of TNF-α, IL-6, and IFN-γ. As CD40-TRAF6 interactions predominantly occur in macrophages, we subjected CD40flfl LysMcre mice to EAE. This myeloid specific deletion of CD40 resulted in a significant reduction in EAE severity, reduced CNS inflammation and demyelination. In conclusion, the CD40-TRAF6 signaling pathway in MHCII+ cells plays a key role in neuro-inflammation and demyelination during EAE. Concomitant with the fact that CD40-TRAF6 interactions are predominant in macrophages, depletion of myeloid CD40 also reduces neuro-inflammation. CD40-TRAF6 interactions thus represent a promising therapeutic target for multiple sclerosis.

KW - CD40

KW - TNF receptor-associated peptides and proteins

KW - experimental autoimmune encephalomyelitis

KW - macrophages

KW - multiple sclerosis

UR - http://www.mendeley.com/research/macrophage-cd40-signaling-drives-experimental-autoimmune-encephalomyelitis

U2 - 10.1002/path.5205

DO - 10.1002/path.5205

M3 - Article

VL - 247

SP - 471

EP - 480

JO - Journal of Pathology

JF - Journal of Pathology

SN - 0022-3417

IS - 4

ER -

Aarts SABM, Seijkens TTP, Kusters PJH, van Tiel CM, Reiche ME, den Toom M et al. Macrophage CD40-signaling drives experimental autoimmune encephalomyelitis. Journal of Pathology. 2019 Apr 1;247(4):471-480. https://doi.org/10.1002/path.5205